STOCK TITAN

Inspira Technologies Oxy B.H.N. Ltd - IINN STOCK NEWS

Welcome to our dedicated news page for Inspira Technologies Oxy B.H.N. (Ticker: IINN), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy B.H.N..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Inspira Technologies Oxy B.H.N.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Inspira Technologies Oxy B.H.N.'s position in the market.

Rhea-AI Summary
Inspira™ Technologies OXY B.H.N. signs a term sheet with Beilinson Hospital in Israel for the evaluation of its INSPIRA ART100 device in organ transplant procedures. Beilinson Hospital, a leading organ transplant center in Israel, will provide data and feedback for the evaluation. The collaboration aims to enhance patient outcomes and expand the use of the device in medical settings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Inspira Technologies and Ennocure MedTech announce successful results in developing a bio-electronic treatment to prevent bloodstream infections, showing a 75% reduction in bacterial growth within 4 hours and 100% reduction within 24 hours. The technology aims to inhibit bacterial proliferation without the use of antiseptic agents, potentially offering advantages over current standard care solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.22%
Tags
none
-
Rhea-AI Summary
Inspira Technologies OXY B.H.N. announces the exploration of INSPIRA ART100 Device for neonatal respiratory support, aiming to replace mechanical ventilators. The potential application targets prematurely born neonates and neonates with life-threatening disorders. CEO Dagi Ben-Noon emphasizes the commitment to improving neonatal care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
none
Rhea-AI Summary
Inspira Technologies OXY B.H.N. (Nasdaq: IINN, IINNW) announces a strategic investment by Mr. Ronen Juster and Ms. Margi Ben-Noon. The company will issue 1,339,285 ordinary shares at $1.232 per share in a registered direct offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.57%
Tags
-
Rhea-AI Summary
Inspira Technologies OXY B.H.N. announces FDA submission for approval of INSPIRA™ ART100, 95% accuracy results for HYLA™ Blood Sensor, and granted U.S. patent, along with financial results and business developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.9%
Tags
-
Rhea-AI Summary
Inspira Technologies OXY B.H.N. announces AMAR submission for approval of the INSPIRA™ ART100, a breakthrough medical device. The company aims to redefine life support with innovative technology, potentially targeting new markets in Southeast Asia and South America.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.3%
Tags
none
Rhea-AI Summary
Inspira Technologies achieves a breakthrough with their VORTX™ device, meeting 100% of regulatory blood oxygenation requirements with zero pressure gradient, potentially revolutionizing medical device technology. The company's U.S. patent with novel claims further enhances its innovative position in the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
none
-
Rhea-AI Summary
Inspira Technologies OXY B.H.N. Ltd. announces a major milestone in core blood oxygenation technology with INSPIRA ART (Gen 2), aiming to revolutionize the medical device market. Anticipated FDA clearance for INSPIRA ART100 (Gen 1) in 2024 to address a $1.16 billion market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.53%
Tags
conferences
-
Rhea-AI Summary
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) announces an Investor Presentation to reveal a major milestone regarding their breakthrough Augmented Respiration Technology. The technology aims to rebalance patient oxygen levels without invasive ventilation systems. The Company President, Mr. Joe Hayon, will present the details on March 4, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.42%
Tags
conferences
Rhea-AI Summary
Inspira Technologies progresses towards FDA 510(k) clearance for INSPIRA ART100 device, plans additional submissions for HYLA blood sensor and INSPIRA ART disposables. Company revolutionizing mechanical ventilator market with proprietary technologies. Signed $546 million in distribution agreements. President emphasizes the importance of HYLA blood sensor in delivering oxygen. Breakthrough patents approved by USPTO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.42%
Tags
none
Inspira Technologies Oxy B.H.N. Ltd

Nasdaq:IINN

IINN Rankings

IINN Stock Data

35.45M
9.57M
9.47%
9.3%
1.39%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Israel
Raanana

About IINN

insense medical develops state of the art respiratory support technology as an alternative to mechanical ventilation by 2020 more than 600,000 patients in the u.s. will require mechanical ventilation. 5.7 million patients are admitted annually to icu's with 35% needing ventilation. cost of treatment is estimated at 64 bn$/y as mortality reaches 40%. imagine that instead of mechanical ventilation, or ecmo treatment, a small and safe apparatus is placed into a vein, replacing necessary lung functions without the devastating complications associated with mechanical ventilation. oxylink, an advanced nano vesicle technology. our revolutionary intravascular oxygenation apparatus, safely increases the level of oxygen & reduces the carbon dioxide in blood, enabling your physician to address the primary ventilatory condition.